FY2028 EPS Estimates for Insulet Lifted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Investment analysts at Leerink Partnrs increased their FY2028 EPS estimates for Insulet in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will post earnings per share of $7.80 for the year, up from their previous estimate of $7.75. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share.

Several other research analysts have also recently issued reports on the stock. Canaccord Genuity Group lifted their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. UBS Group increased their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. BTIG Research boosted their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Piper Sandler increased their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Stock Performance

Insulet stock opened at $266.92 on Wednesday. Insulet has a twelve month low of $160.19 and a twelve month high of $279.40. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $18.72 billion, a P/E ratio of 45.71, a PEG ratio of 4.08 and a beta of 1.22. The stock’s 50 day moving average is $243.21 and its 200 day moving average is $212.74.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently made changes to their positions in the business. Synovus Financial Corp lifted its holdings in Insulet by 36.1% during the 3rd quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock valued at $682,000 after buying an additional 777 shares in the last quarter. Tidal Investments LLC increased its position in shares of Insulet by 5.2% during the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier’s stock worth $2,180,000 after acquiring an additional 466 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Insulet during the third quarter valued at approximately $114,000. Virtu Financial LLC purchased a new stake in shares of Insulet in the third quarter valued at approximately $616,000. Finally, TD Private Client Wealth LLC grew its stake in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.